Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Angiotensin II

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    197 result(s) found for: Angiotensin II. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-004460-66 Sponsor Protocol Number: KARAASS-1 Start Date*: 2014-04-01
    Sponsor Name:Jørgen Jeppesen
    Full Title: Oral potassium supplementation in healthy men - interactions with the renin-angiotensin-aldosterone system and the sympathetic nervous system
    Medical condition: Blood pressure regulation and hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004866 10008393 Change in blood pressure LLT
    16.1 100000004865 10053967 Potassium supplementation LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001172-15 Sponsor Protocol Number: APN01-01-COVID19 Start Date*: 2020-04-08
    Sponsor Name:APEIRON Biologics AG
    Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19
    Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-000727-17 Sponsor Protocol Number: 281274 Start Date*: 2007-08-23
    Sponsor Name:Erasmus MC
    Full Title: Maternal, uteroplacental and fetal haemodynamic effect of Nicardipine in severe pre-eclampsia.
    Medical condition: Hypertensive crisis in patients with severe pre-eclampsia needs to be treated to prevent maternal and fetal complications. The maternal, uteroplacental and fetal haemodynamic respose to antihypert...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040445 Severe pre-eclampsia, antepartum LLT
    9.1 10053094 Doppler echocardiography LLT
    9.1 10045412 Ultrasound Doppler LLT
    9.1 10058179 Hypertensive emergency LLT
    9.1 10038555 Renin LLT
    9.1 10002491 Angiotensin II LLT
    9.1 10053406 Brain natriuretic peptide LLT
    9.1 10001644 Aldosterone LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001267-11 Sponsor Protocol Number: Jens05 Start Date*: 2008-09-29
    Sponsor Name:Department of Nephrology
    Full Title: Saving residual kidney function among haemodialysis patients receiving irbesartan - a double blind randomised study
    Medical condition: We want to investigate if an angiotensin II antagonist (irbesartan) has beneficial effects regarding residual kidney function and heart/vessels among haemodialysis patients.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049415 Renin-angiotensin system inhibition LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-012676-27 Sponsor Protocol Number: FemExp-I Start Date*: 2010-01-24
    Sponsor Name:Wallenberg laboratory
    Full Title: Femoral-Express-I
    Medical condition: Peripheral artery disease. Patients due for by-pass surgery of lower extremity arteries.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10034638 Peripheral vascular disorders NEC HLT
    12.0 10003611 Atherosclerosis of arteries of the extremities, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007881-45 Sponsor Protocol Number: SPP100ANL02T Start Date*: 2009-03-12
    Sponsor Name:University Medical Center Groningen
    Full Title: A double-blind, placebo-controlled, randomized trial investigating the safety and efficacy of Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients w...
    Medical condition: Patients with chronic heart failure and reduced glomerular filtration rate.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038443 Renal failure and impairment HLT
    9.1 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004141-90 Sponsor Protocol Number: 4.0 Start Date*: 2017-02-28
    Sponsor Name:Queen Mary University of London
    Full Title: Stopping Perioperative Angiotensin II Converting Enzyme inhibitors and/or receptor blockers in major non-cardiac surgery (SPACE): a phase II, explanatory, randomised controlled trial.
    Medical condition: Myocardial injury (as measured by plasma troponin) after major surgery.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10061024 Cardiac disorder PT
    20.0 10007541 - Cardiac disorders 10061024 Cardiac disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2006-003991-37 Sponsor Protocol Number: AGO/2006/009 Start Date*: 2006-12-13
    Sponsor Name:University Hospital Gent
    Full Title: Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome
    Medical condition: Marfan syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10026829 Marfan's syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003088-87 Sponsor Protocol Number: WWU20_0016 Start Date*: 2021-11-22
    Sponsor Name:Westfälische Wilhelms-Universität Münster
    Full Title: Biomarker-guided implementation of angiotensin-II (AT-II) to reduce the occurrence of kidney damage after cardiac surgery
    Medical condition: Cardiac surgical patients at high risk for AKI
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10069339 Acute kidney injury PT
    20.1 10038359 - Renal and urinary disorders 10080266 Stage 1 acute kidney injury LLT
    20.1 10038359 - Renal and urinary disorders 10080269 Stage 2 acute kidney injury LLT
    20.1 10038359 - Renal and urinary disorders 10080271 Stage 3 acute kidney injury LLT
    20.0 100000004863 10017501 Functional disturbances following cardiac surgery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-003262-17 Sponsor Protocol Number: AG-1-2007. Start Date*: 2008-08-13
    Sponsor Name:University Hospital Magdeburg
    Full Title: Impact of irbesartan on oxidative stress and C-reactive protein levels in patients with persistent atrial fibrillation
    Medical condition: Blocking the angiotensin II type 1 receptor reduces systemic levels of oxidative stress markers and adhesion molecules compared to placebo in patients with persistent/permanent atrial fibrillation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002262-19 Sponsor Protocol Number: CVAL489ANL09 Start Date*: 2006-08-07
    Sponsor Name:Novartis Pharma B.V.
    Full Title: Angiotensin II receptor blockers in patients with systemic right ventricle.
    Medical condition: Systemic right ventricle due to total transposition of the great arteries or congenitally corrected transposition of the great arteries
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003175-19 Sponsor Protocol Number: U1111-1206-7541 Start Date*: 2019-11-28
    Sponsor Name:Steno Diabetes Center Copenhagen
    Full Title: Renal effects of treatment with Empagliflozin alone or in combination with Semaglutide in patients with type 2 diabetes and albuminuria - A double blinded, randomised, placebo controlled, parallel...
    Medical condition: Type 2 diabetes with renal complications
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006861-18 Sponsor Protocol Number: 20061212 Start Date*: 2007-03-26
    Sponsor Name:Department of Cardiology
    Full Title: Comparison between beta-adrenergic blockers and angiotensin II receptor antagonists for the treatment of late hypertension in patients with repaired aortic coarctation
    Medical condition: Aortic coarctation and late hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003641-15 Sponsor Protocol Number: 2625 Start Date*: 2013-07-04
    Sponsor Name:North Bristol NHS Trust
    Full Title: Reducing pathology in Alzheimer’s Disease through Angiotensin taRgeting. The RADAR Trial. A phase II, two arm, double-blind, placebo-controlled, randomised trial to evaluate the effect of losartan ...
    Medical condition: Alzheimer's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001124-66 Sponsor Protocol Number: 15774603 Start Date*: 2016-07-08
    Sponsor Name:University Hospital Toulouse
    Full Title: Evaluation of the effect of double inhibition of angiotensin II AT1 receptor and neprilysin activity on sympatic nervous system activity in patient with heart failure (B2AN-SNS)
    Medical condition: Heart failure
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001206-35 Sponsor Protocol Number: ACEI-COVID-19 Start Date*: 2020-04-14
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Stopping ACE-inhibitors in COVID-19 - a randomized, controlled clinical trial
    Medical condition: The study will investigate infections with the new SARS-CoV2 virus. Current studies show that the SARS-CoV2 virus penetrates human cells via the angiotensin converting enzyme II (ACE2) receptor 2. ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002935-14 Sponsor Protocol Number: EMPRA Start Date*: 2016-11-22
    Sponsor Name:Medical University of Vienna, Internal Medicine III, Clinical Div. of Nephrology and Dialysis
    Full Title: Effect of empagliflozin on the renin-angiotensin system in patients with chronic kidney disease with and without type 2 diabetes
    Medical condition: Chronic kidney disease with and without type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    20.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001191-12 Sponsor Protocol Number: Salt og Cirrhose Start Date*: 2005-07-06
    Sponsor Name:Odense Universitetshospital
    Full Title: Forebyggelse af inkompenseret levercirrose med Losartan Et prospektivt randomiseret dobbeltblindet lantidsstudie
    Medical condition: Alkoholisk levercirrose. Fibrosedannelse og senere cirrose i leveren efter en årrække med øget indtag/misbrug af alkohol. Komplikationer ses i form af inkomensation med ascites, oesofagusvaricer og...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007516-28 Sponsor Protocol Number: CYT006-AngQb 03 Start Date*: 2008-06-06
    Sponsor Name:Cytos Biotechnology AG
    Full Title: A Double Blind, Randomized, Placebo Controlled, Parallel Group, Dose-Titration Phase II Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Efficacy of an Anti-Angiotensin II Vac...
    Medical condition: Mild to moderate essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001190-25 Sponsor Protocol Number: A6291015 Start Date*: 2004-12-17
    Sponsor Name:Pfizer Ltd
    Full Title: A Double-blind, Proof of Concept Trial of the Use of Pegvisomant to Reduce Urinary Albumin Excretion in Type 1 and Type 2 Diabetic Patients Treated with Angiotensin Convertase Inhibitors/Angiotensi...
    Medical condition: Diabetic nephropathy DN (Diabetes mellitus (DM) type I and type II with renal manifestations). MedDRA classification code : 10061835, 10045236 and 10045250 (Version 7.0, Level LLT)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) CZ (Completed) DE (Completed) GB (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA